Summary
Updated Aug 31, 2026
Paul L. Berns is Title: Executive Chair of the Board, Director of Neumora Therapeutics, Inc. (NMRA). 9 SEC Form 4 filings on record going back to 2024, most recently on 21 August 2026. Most recent open-market trade: bought $20.00M of KARD on 24 June 2026. Lifetime open-market purchases: $20.00M. Lifetime open-market sales: $34K.
Recent Transactions
11Every recent SEC Form 4 transaction Paul L. Berns has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Paul L. Berns go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $20.00M (1 buy totaling $20.00M). The largest single buy on record is $20.00M of KARD in 2026. Sales side: 1 recorded sale totaling $34K, so the filing history runs buy-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Paul L. Berns files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- HRTG GPE, LLC - $50.00M of KARD open-market activity in the last 12 months
- ARCH Venture Partners XIII, LLC - $20.00M of KARD open-market activity in the last 12 months
- Kristina Burow - $5.00M of NMRA open-market activity in the last 12 months
- ARCH Venture Partners X, LLC - $5.00M of NMRA open-market activity in the last 12 months
- ARCH Venture Partners XII, LLC - $5.00M of NMRA open-market activity in the last 12 months
- Daljit Singh Aurora - $1.03M of NMRA open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Paul L. Berns?
Paul L. Berns is a corporate insider, tracked as Title: Executive Chair of the Board, Director of Neumora Therapeutics, Inc. (NMRA). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Paul L. Berns submitted recently?
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Paul L. Berns been buying or selling stock?
Recorded transactions: 1 open-market purchase ($20.00M) and 1 open-market sale ($34K) across all tracked filings.
Where can I see all of Paul L. Berns's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Paul L. Berns and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial